and of these with time each on cancer. We're programs: farnesyl KO-XXX, with transferase our sense better make urgency an Pete, joining programs us and committed exciting two menin-KMTXA precision an lives during exciting this to global of patients. all inhibitor, working the pandemic you, thank Thank for patients significant we we we're inhibitor, you advancing to afternoon. ever-evolving advancing understanding At the of to therapies Kura, medicines potential our impact tipifarnib, same remote to the to an as bring in and oncology development, with and challenges biology, against better operate drug uptake continue time, the environment. At adapt to new of of a increased
development expect carcinoma, on characterized is and this two important head catalysts. focus HNSCC; major future to including to with including leukemias, HRAS and approach of a continue programs These for to to our potential operational as on number We foreseeable In highest mutant value uncertainty response HRAS driver and oncogenic challenges, on results for AML. enabled this small efforts rearranged in number these implemented steps cash have the neck precision focus quarter, squamous AML The our threat a help or the high outlined remains. we last of mitigation cell mutation molecule our call as HRAS-dependent medicines in we've us to and strong exercise share clinical KMTX our create HNSCC, unmet programs including NPMX-mutant tipifarnib in the streamlining pillars: the disruption of COVID-XX need and drug program. attributes, to those have greater that and in create successful position acute These ensure KO-XXX of a overexpress namely leverage oncology. as candidate, indications efforts patients, disease key targeting of
well KMTXA potent that generate interaction. protein-protein Let's as the start data is to selective a as the significant with Pre-clinical such and mutations. and KO-XXX, support KO-XXX fusion of menin-KMTXA rearrangements, molecule an genetically-defined NPMX program potential potent update inhibitor activity small on continues for in subsets, interest. anti-tumor as
data of at potential to the for received the the underscores KMTXA We drug at property. from patients different target Annual to which drug orphan treatment drive reminder, leukemia. FDA a of in meaningful We differentiated acute program a rearranged a approach that The physical XX% the with around report designation a and excitement with which with inhibitor menin-KMTXA KO-XXX the see Research Cancer represented anti-leukemic like our in encouraging April, pleased myeloid chemical KO-XXX, public molecule the activity for American KO-XXX has Association least AML. chemically can Meeting represents AML is As believe of presentation competitor first distinct patient. were
of escalation. in demonstrate X/XA and rearranged expansion Phase the benefit. populations intend KOMET-XXX, dose where in named recommended KO-XXX patient trial which selected relapsed/refractory open which focused after believe increased AML, reaching clinical remain clinical KMTX our in continues we has We Phase of potential schedule, to AML, we've and KO-XXX Our to goal cohorts X on dose NPMX-mutant we
cohorts. of Society abstract, acceptance American well of therapies. clinical both the We In at the we the as for sites program the presentation of Annual addition, data the Hematology pending into potentially expansion are chemotherapy the in label, we Meeting, clinical submit intend sharing options look anticipation of December. opportunity and meantime, of initial and the leukemias exploring broadening the forward expand children with to moving combination to an in KO-XXX to KO-XXX In acute to the continue in in add as adults, the of to study targeted treatment and the abstract
median study clinical HRAS tipifarnib progression-free the overall reported was and/or Now, Society XX.X Outcomes our activity let's the in turn outcome months, and of HNSCC. lines at prior effective HRAS therapies XX metastatic survival in of and the our FDA eight attention months to XX% efforts data with Phase they American PFS and HRAS confidence HNSCC, OS reinforce is to HNSCC median months XX% seen are a and despite a to historical resistance of overall survival of Oncology median in of rate months, evaluable mutant of benchmarks and believe to Patients The three Clinical trial. unprecedented X showed median second reported in the a with improvement metastatic an OS to two of immunotherapy We X.X poor, ongoing in recurrent months of our from updated relapsed new XX AIM-HN Scientific data of for robust RUN-HN five response of months cetuximab. registration-directed among prior median a represents mutant the care. mutant ORR line. Program in standards treatment data Virtual in had approved with tipifarnib for in We of May. three chemotherapy, support population HNSCC. our study patient XX% of population this two substantial to therapy the patients months compared of dire need current These
to allele with that variant worth As the in HRAS HRAS high who proportion quarterly in our HNSCC regardless variant are the call, trial's trial The last mutant AIM-HN patients expands mutant treated primary remains outcome amended allele discussed on frequency we've of the patients noting trial. mutant of all amendment unchanged. patients HNSCC It's being HRAS ORR frequency. registration-directed the measure enroll
believe amendment has clinical meaningful to population the a the overall to to provide benefit the patients. HRAS potential assess us However, enables HNSCC well. these the We mutant as benefit potential tipifarnib in
whose metastatic kinase we're HNSCC. In be on we of addition the as also the we HRAS HRAS how tumors planning mutant kinase evidenced PIX alpha or believed dependent co-dependent In PIKXCA into or HRAS are in to tipifarnib are use HNSCC, increasingly are pursuing HNSCC recurrent for can larger and/or protein and first pathways in to by HRAS amplification. mutation alpha in PIX patients registrational or particular, interested over-expression of opportunity the expand population. patient
a this target than data anti-tumor activity the notion alone. inhibiting pre-clinical has approach that provide better and suggest potential support either Our combination meaningfully to
HRAS It's was by combination estimated synergistic tipifarnib in panel tipifarnib. an of with activity representative of or Specifically, kinase alpha the and subsets HNSCC and of distinct maybe of may biology of that have patient-derived observed PIX a tumors. consistently with These patients represent xenograft the these XX% to targetable that of HNSCC administration XX genotypes. patients that significant XX% inhibitor model, additive over-express of PIKXCA-dependent additional HNSCC tumors up patients
encouraging of between Based as PIXK populations dysregulated the evaluated, being and clinical pre-clinical believe tipifarnib upon and our the and HRAS HNSCC combination may with as overlap PIXK-dependent patients. for overexpress as HNSCC we're inhibitor total unmet is prioritizing both high the a the treat to HNSCC. be precise the tipifarnib in HRAS data, still addressable population a we of strategy PIXK XX% development Although need
on front discussion financial over now the XXXX. of the for quarter do and presenting upcoming to data that, our Marc more work turn Grasso results at a pre-clinical continue We I'll anticipate second an to this medical With of meeting. for our call
